Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway.
Chin J Nat Med
; 22(4): 318-328, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38658095
ABSTRACT
Double cortin-like kinase 1 (DCLK1) exhibits high expression levels across various cancers, notably in human colorectal cancer (CRC). Diacerein, a clinically approved interleukin (IL)-1ß inhibitor for osteoarthritis treatment, was evaluated for its impact on CRC proliferation and migration, alongside its underlying mechanisms, through both in vitro and in vivo analyses. The study employed MTT assay, colony formation, wound healing, transwell assays, flow cytometry, and Hoechst 33342 staining to assess cell proliferation, migration, and apoptosis. Additionally, proteome microarray assay and western blotting analyses were conducted to elucidate diacerein's specific mechanism of action. Our findings indicate that diacerein significantly inhibits DCLK1-dependent CRC growth in vitro and in vivo. Through high-throughput proteomics microarray and molecular docking studies, we identified that diacerein directly interacts with DCLK1. Mechanistically, the suppression of p-STAT3 expression following DCLK1 inhibition by diacerein or specific DCLK1 siRNA was observed. Furthermore, diacerein effectively disrupted the DCLK1/STAT3 signaling pathway and its downstream targets, including MCL-1, VEGF, and survivin, thereby inhibiting CRC progression in a mouse model, thereby inhibiting CRC progression in a mouse model.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Signal Transduction
/
Anthraquinones
/
Protein Serine-Threonine Kinases
/
Intracellular Signaling Peptides and Proteins
/
Cell Proliferation
/
STAT3 Transcription Factor
/
Doublecortin-Like Kinases
Language:
En
Journal:
Chin J Nat Med
Year:
2024
Type:
Article
Affiliation country:
China